

Erratum

In the article by Reich et al. [Dermatology 2010;221:172–178], entitled ‘Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS trial’, in table 3 on page 175, there was an unintentional error pertaining to median DLQI improvement percentages. Specifically, the mean DLQI improvement percentages for week 38 scores, i.e. 92.9% for all, 100.0% for PASI-75 responders and 100.0% for PASI-90 responders, should not have been included. The data points in the table should be replaced by dashes because there were no DLQI assessments at that time point in the EXPRESS study. The error did not affect the interpretation or conclusions of the study.